Daratumumab and hyaluronidase-fihj news

All news on Daratumumab and hyaluronidase-fihj (also known as DARZALEX FASPRO and DARZALEX): plants, production capacities, investments and involved companies.

6 January 2026

Johnson & Johnson Seeks EMA Approval for TECVAYLI and DARZALEX Combo in Relapsed Multiple Myeloma

The EMA application is based on Phase 3 data showing improved survival in relapsed multiple myeloma with TECVAYLI and DARZALEX, with similar adverse event rates to standard care.
15 December 2025

Janssen's TECVAYLI® and DARZALEX FASPRO® Join FDA's Priority Voucher Program

TECVAYLI® and DARZALEX FASPRO® show significant survival benefits in multiple myeloma, gaining FDA Breakthrough Therapy Designation and Real-Time Oncology Review.
9 December 2025

Johnson & Johnson's Phase 3 Study: TECVAYLI® and DARZALEX FASPRO® Show Promise for Relapsed/Refractory Multiple Myeloma

TECVAYLI® plus DARZALEX FASPRO® reduces disease progression risk by 83% in RRMM patients, showing improved survival and quality of life over standard care.
6 November 2025

Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma

DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.

Who will be producing Daratumumab and hyaluronidase-fihj in the future?

Find out with chemXplore Analytics